Editas Medicine (EDIT) Change in Receivables (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Change in Receivables data on file, last reported at $7.5 million in Q3 2025.

• On a quarterly basis, Change in Receivables rose 6491.53% year-over-year to $7.5 million in Q3 2025; TTM through Sep 2025 was $8.0 million, a 448.61% increase from a year earlier, with the FY2024 full-year figure at $6.1 million, up 20.57% from the prior year.
• Change in Receivables for Q3 2025 stood at $7.5 million, up from $78000.0 in the prior quarter.
• Over the last five years, Change in Receivables for EDIT reached as high as $16.1 million in Q4 2024 and fell as low as -$15.8 million in Q1 2025.
• Historically, Change in Receivables has averaged $109578.9 across 5 years, with a median of -$1000.0 in 2024.
• Across the five-year window, Change in Receivables tumbled 1133.33% in 2021 and soared 31306.25% in 2022, its largest moves.
• Year by year, Change in Receivables stood at $16000.0 in 2021, then surged by 31306.25% to $5.0 million in 2022, then surged by 54.53% to $7.8 million in 2023, then jumped by 107.86% to $16.1 million in 2024, then slumped by 53.27% to $7.5 million in 2025.
• Per Business Quant data, the three most recent Change in Receivables figures were $7.5 million in Q3 2025, $78000.0 in Q2 2025, and -$15.8 million in Q1 2025.